30 Jun 2020 11:00
30 June 2020
Clinigen Group plc
("Clinigen" or the "Group")
Total Voting Rights and Capital
In conformity with Rule 5.6.1 of the Disclosure Guidance and Transparency Rules, the Group notifies the market that as at 30 June 2020, Clinigen's issued share capital consists of 132,898,771 ordinary shares of 0.1 pence each with voting rights. No shares are held in Treasury.
The above figure of 132,898,771 may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the FCA's Disclosure Guidance and Transparency Rules.
- Ends -
For further information, please contact:
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Matt Parrish, Head of Investor Relations | |
J.P.Morgan Cazenove - Nominated Adviser & Joint Broker | Tel: +44 (0)20 7742 4000 |
James Mitford / Hemant Kapoor | |
RBC Capital Markets - Joint Broker | Tel: +44 (0)20 7653 4000 |
Marcus Jackson / Elliot Thomas | |
Instinctif Partners Melanie Toyne Sewell / Phillip Marriage | Tel: +44 (0)20 7457 2020 Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com.